Beactica, the Swedish drug discovery company, has signed a three-year extension of its master services agreement with Sanofi. The agreement outlines the legal terms under which Beactica and Sanofi collaborate on the characterization of interactions between novel therapeutics and their target proteins. As part of the collaboration, Beactica scientists have supported Sanofi with analysis of the interaction kinetics between insulin analogues and their two binding sites on the full-length insulin...